Table 1.
Total Sample | BPD | DD | NAD | Statistic | |
---|---|---|---|---|---|
N (%) | 605 | 79 (13.1%) | 388 (64.1%) | 138 (22.8%) | - |
Socio-demographic variables | |||||
Age: Mean [Range]a | 39.2 [17–92] | 39.5 [20–81] | 38.3 [17–76] | 41.9 [18–92] | F = 3.44* |
Sex, female: n (%) | 363 (60.0%) | 51 (64.6%) | 236 (60.8%) | 76 (55.1%) | χ2 = 2.19 |
Caucasian: n (%) | 531 (89.4%) | 71 (92.2%) | 341 (88.8%) | 119 (89.5%) | χ2 = .786 |
Married: n (%) | 236 (40.8%) | 26 (33.8%) | 148 (39.7%) | 62 (48.1%) | χ2 = 4.59 |
College graduate: n (%) | 328 (54.2%) | 47 (59.5%) | 203 (52.3%) | 78 (56.5%) | χ2 = 1.74 |
Treatment variables n (%) | |||||
Any treatment | 521 (86.1%) | 71 (89.9%) | 346 (89.2%) | 104 (75.4%) | χ2 = 17.32*** |
CBT | 169 (27.9%) | 19 (24.1%) | 120 (30.9%) | 30 (22.7%) | χ2 = 4.95 |
Benzo’s | 291 (48.1%) | 47 (59.5%) | 204 (52.6%) | 40 (29.0%) | χ2 = 27.42*** |
SRI’s | 482 (79.7%) | 67 (84.8%) | 325 (83.8%) | 90 (65.2%) | χ2 = 23.10*** |
Tricyclics | 133 (22.0%) | 24 (30.4%) | 97 (25.0%) | 12 (8.7%) | χ2 = 19.51*** |
Mood Stabilizers | 178 (29.4%) | 49 (62.0%) | 107 (27.6%) | 22 (15.9%) | χ2 = 53.15*** |
Neuroleptics | 193 (31.9%) | 44 (55.7%) | 129 (33.2%) | 20 (14.5%) | χ2 = 40.17*** |
p < .001
p < .05
DD group significantly different than the NAD group (p<.05)